Comparison

Ketamine vs SSRIs

SSRIs are the first-line antidepressant for most people. Ketamine is typically considered after SSRIs and other options have not produced adequate response, or in specific clinical contexts.

Written by: Ira ZootMedical review status: Not yet clinically reviewed.Last updated: June 4, 2026Evidence: Educational synthesis - not medical advice

This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.

Quick answer

Bottom line

Not competitors. SSRIs remain a standard first step; ketamine is an option when standard options have not worked or in specific clinical contexts, ideally within a comprehensive plan.

This page compares Ketamine and SSRIs across the same fixed dimensions - mechanism, evidence, onset, duration, side effects, access, suitability, and limits. It does not name a winner and does not recommend either option for you.

Related on Ketalux

Ketamine

SSRIs

Mechanism

NMDA-receptor antagonism with downstream effects on glutamate signaling, BDNF, and synaptic plasticity.

Inhibition of serotonin reuptake, gradually modulating serotonergic signaling and downstream neuroplasticity.

Evidence

Robust short-term antidepressant effect in TRD; durability requires repeat dosing and integration.

Largest body of long-term evidence across depression and anxiety; modest average effect size.

Onset

Hours to days for many responders.

Two to six weeks for typical response.

Duration

Days to weeks per session without maintenance.

Ongoing while taken as prescribed.

Side effects

Transient dissociation, blood pressure changes, nausea, dizziness; bladder effects with frequent recreational use.

Sexual dysfunction, GI symptoms, sleep changes, emotional blunting; discontinuation symptoms.

Access

Specialty clinics, IV/IM/intranasal; not first-line.

Primary care and psychiatry; widely available.

Best for

Treatment-resistant depression, certain acute scenarios, patients who have not tolerated or responded to standard options.

First-line pharmacological treatment of moderate-to-severe depression and several anxiety disorders.

Limits

Cost, access, durability without integration, limited long-term safety data at therapeutic doses.

Slow onset, partial response common, side-effect burden for some patients.

Disclaimer

This comparison is educational and general. It is not a recommendation. Treatment choice depends on your individual history, diagnosis, prior response, preferences, and access - discuss with a qualified clinician.

About the author

Ira Zoot

Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →

Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.